- Accueil
- Research
- Our research groups
- Immunotherapy and biomarkers for immuno-oncology
Immunotherapy and biomarkers for immuno-oncology
Team
Alessandra NOTO | PhD, Senior Scientist |
| Victor JOO | PhD, Senior Scientist |
| Federica MARTINA | PhD, Biostatistician |
Douglas DAOUDLARIAN | Data manager |
Research Focus
Our laboratory’s primary interest lies in unraveling the molecular and cellular pathogenesis of immunotoxicities with a focus on the discovery of new biomarkers for cancer immunotherapy, novel therapeutic targets for refractory irAEs, and immuno-modulation strategies to improve current therapies and develop the next generation cancer immunotherapies. Among the most challenging questions in identifying novel biomarkers for cancer immunotherapy is the characterization of the different immunological and physiological factors modulating irAEs and responses to cancer immunotherapy. Work in the Obeid lab takes advantage of the latest technology and leverages multi-omic methods including CyTOF and single-cell profiling of immune cells and in collaboration with clinicians and scientists across the Lausanne biomedical network.
I believe that the main objective of work in my lab is to provide a deep dissection of the immune system to conceive the next generation of immunotherapies in order to make cancer immunotherapy safer and more effective.
Current projects Covers
Our lab has several highly integrated human immunology projects:
- Decoding the pathogenesis of immunotoxicities
- Identification of new biomarkers for cancer immunotherapies (immune checkpoints inhibitors and CAR-T cell therapies)
- Developing new generation of immune checkpoints inhibitors (ICIs)
- Developing new immuno-modulation strategies to prevent and optimize the treatment of immune-related adverse events induced by CAR-T cell therapy and ICIs
Selected Publications
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S, Michielin O
Front Oncol. 2022;12:1043675
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.
Ann Oncol. 2022 Oct 18
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M
J Immunother Cancer. 2022 Oct;10(10)
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Stalder G, Suffiotti M, Segot A, Noto A, Pantaleo G, Spertini O, Obeid M
Haematologica. 2022 Sep 8
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, Stevenel C, Hottinger R, Pythoud C, Coutechier L, Molinari L, Trono D, Ribi C, Gottardo R, Fenwick C, Pascual M, Duchosal MA, Peters S, Pantaleo G
JAMA Oncol. 2022 May 1;8(5):e220446
<sup>68</sup>Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M
J Immunother Cancer. 2021 Oct;9(10)
Reactivation of IgA vasculitis after COVID-19 vaccination.
Obeid M, Fenwick C, Pantaleo G
Lancet Rheumatol. 2021 Sep;3(9):e617
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M
J Thorac Oncol. 2021 Feb;16(2):318-326
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
Özdemir BC, Latifyan S, Perreau M, Fenwick C, Alberio L, Waeber G, Spertini F, de Leval L, Michielin O, Obeid M
Ann Oncol. 2020 Dec;31(12):1775-1778
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Doms J, Prior JO, Peters S, Obeid M
Ann Oncol. 2020 Sep;31(9):1273-1275
Personalized treatment of immune-related adverse events - balance is required.
Martins F, Obeid M
Nat Rev Clin Oncol. 2020 Aug;17(8):517
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M
J Immunother Cancer. 2020 Jun;8(1)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M
Ann Oncol. 2020 Jun;31(6):724-744
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Addeo A, Obeid M, Friedlaender A
J Immunother Cancer. 2020 May;8(1)
A Diffuse Medullary Hypercaptation With No Bone Lesion.
Christin A, de Leval L, Obeid M
JAMA Oncol. 2020 Feb 1;6(2):291-292
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Lancet Oncol. 2019 Jan;20(1):e54-e64
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M
J Immunother Cancer. 2018 Dec 27;6(1):156
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M
J Immunother Cancer. 2018 Oct 22;6(1):110
Ecto-calreticulin in immunogenic chemotherapy.
Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G
Immunol Rev. 2007 Dec;220:22-34
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis.
Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G
Cell Death Differ. 2007 Oct;14(10):1848-50
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, A
Nat Med. 2007 Sep;13(9):1050-9
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G
Nat Med. 2007 Jan;13(1):54-61
Service d'immunologie et allergie
BH10-527
Rue du Bugnon 46
1011 Lausanne
+41 21 314 0790
Service d'immunologie et allergie
BH10-527
Rue du Bugnon 46
1011 Lausanne
+41 21 314 0790